image: Human Gene Therapy, the official journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Led by Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its companion journals, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. view more
Credit: ©Mary Ann Liebert, Inc., publishers
New Rochelle, NY, August 24, 2015--Chimeric antigen receptor (CAR) T cells, which can specifically recognize and target tumor cells, have resulted in complete responses in patients with leukemia, and although equally promising for treating lymphoma, obstacles remain and individual patient responses CAR T cell therapy have varied. The main barriers to overcome in developing the next generation of CAR T cell therapy are presented in a Review article that is part of a special Nordic issue of Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Human Gene Therapy website until September 30, 2015.
In "CAR T Cell Therapy - The Role of Physical Barriers and Immunosuppression in Lymphoma", coauthors Gunilla Enblad, Hannah Karlsson, and Angelica Loskog, Uppsala University, Sweden, describe a study in which they are evaluating factors related to tumor biology and immunology compared to treatment response in patients with lymphoma participating in a clinical trial of third-generation CAR T cells. The authors explore topics such as CAR T cell design, physical barriers that prevent the cells from infiltrating into tumors, inhibitory substances released by tumors that directly interfere with T cell growth and activity, and the importance of preconditioning therapy for patients receiving treatment with CAR T cells.
Leading the special Nordic issue of Human Gene Therapy is Guest Editor Johanna Laakkonen, PhD, University of Eastern Finland, Kuopio, with Co-Guest Editors Hanna Lesch, FKD Therapies, Kuopio, Finland, and C.I. Edvard Smith, Karolinska Institutet, Karolinska University Hospital Huddinge, Sweden.
"CAR T cell technology is revolutionizing immunotherapy for cancer. This new original work defines important barriers to fully realizing its potential in patients with lymphoma," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA.
###
About the Journal
Human Gene Therapy, the official journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Led by Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its companion journals, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of contents for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.
About the Publisher
Mary Ann Liebert, Inc., publishers) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Nucleic Acid Therapeutics, Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Journal
Human Gene Therapy